Celcuity (CELC) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Celcuity

NasdaqCM•Healthcare•Biotechnology

$84.81+2.23(0.03%)Market open

Market Cap

$4.65B

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

How this company scores

WeakMetricSide Score: 24/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Balance Sheet & Red Flags (8/25); weakest: Profitability (4/25).

Profitability4/25

Growth6/25

Balance Sheet & Red Flags8/25

Cash & Earnings Quality6/25

Grade capped at D

Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/B · 110.2x5y range 1.8x – 110.2x

Currently above its 17-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $4.65B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-208.48M
TTM Op. Income: $-208.68M
Q. Op. Income: $-66.12M
TTM Net Income: $-226.48M
Q. Net Income: $-78.86M
EPS: $-1.44
Shares Out.: $54.82M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-208.48M and TTM operating income of $-208.68M show growth is flowing through to the bottom line. However, net income is negative at $226.48M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -6611800000.0%
Net Margin: -7886400000.0%

Op. margin of -6611800000.0% is down 2210900000.0% YoY — costs are rising relative to revenue. Net margin at -7886400000.0% Across the last 8 quarters, operating margin has fallen for 3 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: N/A

P/S of 0.0x and P/B of 0.0x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $828.22M
Cash: $182.05M
Long-Term Debt: $753.24M
Book Value: $-12.78M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-55.43M
TTM Free Cash Flow: $-192.16M
FCF Margin: N/A
FCF / Net Income: 0.8

TTM FCF of $-192.16M on $-55.43M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 7 consecutive quarters — a weakening trend.